TRV027   Click here for help

GtoPdb Ligand ID: 6902

Synonyms: TRV 120027 | TRV-027 | TRV-120027 | TRV120027
Comment: TRV027 (TRV120027) is a synthetic analogue of endogenous angiotensin II peptide [5]. It acts as a β-arrestin biased ligand of the angiotensin II type 1 receptor (AT1R). TRV027 inhibits angiotensin II-mediated vasoconstriction, increases cardiomyocyte contractility and induces an anti-apoptotic effect, all of which when combined, provide a cardioprotective result.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Click here for help
Canonical SMILES CNCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)O)C)Cc1[nH]cnc1)[C@H](CC)C)Cc1ccc(cc1)O)C(C)C)CCCN=C(N)N
Isomeric SMILES CNCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)O)C)Cc1[nH]cnc1)[C@H](CC)C)Cc1ccc(cc1)O)C(C)C)CCCN=C(N)N
InChI InChI=1S/C43H67N13O10/c1-7-24(4)35(40(63)53-31(19-27-20-47-22-49-27)41(64)56-17-9-11-32(56)38(61)50-25(5)42(65)66)55-37(60)30(18-26-12-14-28(57)15-13-26)52-39(62)34(23(2)3)54-36(59)29(51-33(58)21-46-6)10-8-16-48-43(44)45/h12-15,20,22-25,29-32,34-35,46,57H,7-11,16-19,21H2,1-6H3,(H,47,49)(H,50,61)(H,51,58)(H,52,62)(H,53,63)(H,54,59)(H,55,60)(H,65,66)(H4,44,45,48)/t24-,25+,29-,30-,31-,32-,34-,35-/m0/s1
No information available.
Summary of Clinical Use Click here for help
In vivo, the compound's action is cardioprotective [1-2], and was progressed to Phase 2 clinical trial (NCT01966601) in patients suffering from acute decompensated heart failure [4]. First-in-human results from dosing in healthy volunteers were reported in 2012 [4]. In 2017 it was reported that TRV027 therapy in patients with acute heart failure (AHF) did not improve clinical status through 30-day follow-up compared with placebo [3].

COVID-19: As the SARS-CoV-2 virus binds to ACE2 in the lungs, and effectively downregulates its normal function, levels of angiotensin II (ATII) increase. This drives overactivation of the AT1 receptor, and this likely contributes towards downstream acute lung injury. As a functional AT1 receptor antagonist, TRV027 has potential to reverse the effects of elevated ATII. A clinical trial of TRV027 (NCT04419610; Imperial College London) will be carried out to establish if antagonising the renin-angiotensin system has efficacy to combat acute lung injury and ARDS in COVID-19 patients. If successful this would offer an additional option to anti-virals and anti-inflammatory therapies to address the umet clinical need for treatments for this multi-system, multi-organ disease.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01514578 Single Ascending Dose Study of Intravenous TRV130A in Healthy Adult Males Phase 1 Interventional Trevena Inc. 4
NCT04419610 RAS and Coagulopathy in COVID19 Early Phase 1 Interventional Imperial College London 4
NCT00004030 VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin Phase 1/Phase 2 Interventional Georgetown University 3